Pulmonx Co. (NASDAQ:LUNG) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Pulmonx Co. (NASDAQ:LUNG) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $16.33.

Several equities research analysts have recently weighed in on LUNG shares. Stifel Nicolaus lifted their target price on shares of Pulmonx from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Canaccord Genuity Group dropped their price objective on Pulmonx from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, May 2nd. Piper Sandler restated an “overweight” rating and set a $17.00 target price on shares of Pulmonx in a research report on Wednesday, April 3rd. Wells Fargo & Company reiterated an “equal weight” rating and issued a $14.00 target price (down from $16.00) on shares of Pulmonx in a report on Friday, February 23rd. Finally, Citigroup increased their price target on Pulmonx from $16.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, February 23rd.

Insider Buying and Selling at Pulmonx

In other news, insider Geoffrey Beran Rose sold 3,097 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $9.06, for a total transaction of $28,058.82. Following the transaction, the insider now directly owns 239,952 shares of the company’s stock, valued at $2,173,965.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.60, for a total value of $292,000.00. Following the transaction, the chief executive officer now owns 1,121,344 shares of the company’s stock, valued at approximately $16,371,622.40. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Geoffrey Beran Rose sold 3,097 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $9.06, for a total value of $28,058.82. Following the sale, the insider now directly owns 239,952 shares of the company’s stock, valued at $2,173,965.12. The disclosure for this sale can be found here. Over the last quarter, insiders sold 39,032 shares of company stock valued at $469,012. Company insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of LUNG. FMR LLC lifted its stake in Pulmonx by 24.7% during the 3rd quarter. FMR LLC now owns 2,029,835 shares of the company’s stock valued at $20,968,000 after acquiring an additional 401,830 shares in the last quarter. Walleye Capital LLC bought a new position in shares of Pulmonx during the third quarter valued at about $3,846,000. Primecap Management Co. CA boosted its holdings in Pulmonx by 2.2% during the fourth quarter. Primecap Management Co. CA now owns 5,646,451 shares of the company’s stock worth $71,992,000 after purchasing an additional 124,050 shares during the last quarter. Barclays PLC grew its position in Pulmonx by 132.7% in the 3rd quarter. Barclays PLC now owns 92,938 shares of the company’s stock worth $960,000 after purchasing an additional 53,001 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC increased its stake in Pulmonx by 88.8% in the 4th quarter. Campbell & CO Investment Adviser LLC now owns 85,672 shares of the company’s stock valued at $1,092,000 after buying an additional 40,292 shares during the last quarter. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Pulmonx Stock Performance

NASDAQ LUNG opened at $9.28 on Tuesday. The company has a market capitalization of $357.65 million, a price-to-earnings ratio of -6.03 and a beta of 0.66. Pulmonx has a twelve month low of $7.11 and a twelve month high of $14.84. The stock has a fifty day simple moving average of $8.58 and a 200 day simple moving average of $10.73. The company has a quick ratio of 5.77, a current ratio of 6.50 and a debt-to-equity ratio of 0.30.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings data on Wednesday, May 1st. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. Pulmonx had a negative return on equity of 46.61% and a negative net margin of 80.46%. The company had revenue of $18.85 million for the quarter, compared to analyst estimates of $17.54 million. During the same period in the previous year, the firm earned ($0.42) earnings per share. Sell-side analysts expect that Pulmonx will post -1.63 EPS for the current year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.